Drug Profile
Research programme: Gram-negative infection bacteriocins - Novacta
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Unknown
- Developer Novacta
- Class Proteins
- Mechanism of Action Growth inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Gram-negative infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Gram-negative-infections in United Kingdom (Parenteral)